The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Open accessAbstract
BACKGROUND: Recognizing the rapidly increasing interest and evidence in using metastasis-directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO convened a committee to establish consensus regarding definitions of OMD and define gaps in current evidence. METHODS: A systematic literature review focused on curative intent MDRT was performed in Medline, Embase and Cochrane. Subsequent consensus opinion, using a Delphi process, highlighted the current state of evidence and the limitations in the available literature. RESULTS: Available evidence regarding the use of MDRT for OMD mostly derives from retrospective, single-centre series, with significant heterogeneity in patient inclusion criteria, definition of OMD, and outcomes reported. Consensus was reached that OMD is largely independent of primary tumour, metastatic location and the presence or length of a disease-free interval, supporting both synchronous and metachronous OMD. In the absence of clinical data supporting a maximum number of metastases and organs to define OMD, and of validated molecular biomarkers, consensus supported the ability to deliver safe and clinically meaningful radiotherapy with curative intent to all metastatic sites as a minimum requirement for defining OMD in the context of radiotherapy. Systemic therapy induced OMD was identified as a distinct state of OMD. High-resolution imaging to assess and confirm OMD is crucial, including brain imaging when indicated. Minimum common endpoints such as progression-free and overall survival, local control, toxicity and quality-of-life should be reported; uncommon endpoints as deferral of systemic therapy and cost were endorsed. CONCLUSION: While significant heterogeneity exists in the current OMD definitions in the literature, consensus was reached on multiple key questions. Based on available data, OMD can to date be defined as 1-5 metastatic lesions, a controlled primary tumor being optional, but where all metastatic sites must be safely treatable. Consistent definitions and reporting are warranted and encouraged in ongoing trials and reports generating further evidence to optimize patient benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Self-citationOst, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00201 · Cited by 1,283
Self-citationGuckenberger, M., Lievens, Y., Bouma, A. B., Collette, L., Dekker, A., deSouza, N. M., Dingemans, A.-M. C., Fournier, B., Hurkmans, C., Lecouvet, F. E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30718-1 · Cited by 1,111
Self-citationGomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30532-0 · Cited by 1,086
Self-citationIyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3501 · Cited by 1,047
Self-citation
Cited by
Management of Salivary Gland Malignancy: ASCO Guideline
Geiger, J. L., Ismaila, N., Beadle, B., Caudell, J. J., Chau, N., Deschler, D., Glastonbury, C., Kaufman, M., Lamarre, E., Lau, H. Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00449 · Cited by 441
Contemporary radiotherapy: present and future
Chandra, R. A., Keane, F. K., Voncken, F. E. M., & Thomas, C. R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00233-6 · Cited by 380
Tsai, C. J., Yang, J. T., Shaverdian, N., Patel, J., Shepherd, A. F., Eng, J., Guttmann, D., Yeh, R., Gelblum, D. Y., Namakydoust, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01857-3 · Cited by 283
Self-citationOligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
Miller, E. D., Hitchcock, K. E., & Romesser, P. B. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00900-5 · Cited by 31
Minimally invasive interventional procedures for metastatic bone disease: A comprehensive review
Papalexis, N., Parmeggiani, A., Peta, G., Spinnato, P., Miceli, M., & Facchini, G. (2022) · Current Oncology · doi:10.3390/curroncol29060332 · Cited by 29
Metadata
- Authors
- Lievens, Y., Guckenberger, M., Gomez, D., Hoyer, M., Iyengar, P., Kindts, I., Méndez Romero, A., Nevens, D., Palma, D., Park, C., Ricardi, U., Scorsetti, M., Yu, J., & Woodward, W. A.
- Venue
- Radiotherapy and Oncology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 148
- Pages
- 157-166
- ISSN
- 0167-8140 (ISSN-L)
- OpenAlex
- W3019546741
- Cited by
- 672
- References
- 87
- FWCI
- 71.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. https://app.cochat.ai/papers/10.1016/j.radonc.2020.04.003
- The paper
- Lievens, Y., Guckenberger, M., Gomez, D., Hoyer, M., Iyengar, P., Kindts, I., Méndez Romero, A., Nevens, D., Palma, D., Park, C., Ricardi, U., Scorsetti, M., Yu, J., & Woodward, W. A. (2020). Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology. https://doi.org/10.1016/j.radonc.2020.04.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.